Skip to main content
. Author manuscript; available in PMC: 2013 Jul 16.
Published in final edited form as: Bone. 2012 Sep 29;52(1):145–156. doi: 10.1016/j.bone.2012.09.029

Fig. 5.

Fig. 5

Effects of down-regulation of β-catenin activity on BMP2 expression. (A) Effects of BMP or Wnt antagonists on β-catenin/TCF4 activation of BMP2 promoter activity. C2C12 cells were co-transfected with −2712/+165-Luc reporter and expression vectors for β-catenin and TCF4. Cells were treated with noggin at 500 ng/mL or DKK1 at 100 ng/mL for 36 h. Relative luciferase activity in the cell lysates was measured and normalized by β-gal activity. *: P<0.01 β-catenin/TCF4 vs. vector; #: P<0.05 noggin or DKK1 vs. vehicle (n=6). (B and C) Effects of FWD1/β-TrCP on Wnt signaling activity or BMP2 promoter activity. C2C12 cells were co-transfected with TOPFLASH (B) or −2712/+165-Luc reporter (C) and expression vectors for β-catenin and TCF4, and expression vectors for wild-type β-TrCP (FWD1) or mutant β-TrCP (FWD1ΔF) for 36 h. Relative luciferase activity in the cell lysates was measured and normalized by β-gal activity. In (B): *: P<0.01 FWD1ΔF vs. vector, or FWD1ΔF+β-catenin/TCF4 vs. vector+β-catenin/TCF4; #: P<0.05 FWD1+β-catenin/TCF4 vs. vector+β-catenin/TCF4. In (C): *: P<0.05 FWD1 vs. vector, or FWD1+β-catenin/TCF4 vs. vector+β-catenin/TCF4 (n=6).